ClinicalTrials.gg
TerminatedNCT03319771Updated Oct 11, 2021

Exercise and Learning and Memory in Multiple Sclerosis

An interventional study of Treadmill Walking Exercise Training and Stretching-and-toning Exercise Training in Multiple Sclerosis, Physical Activity and Memory Impairment, sponsored by University of Alabama at Birmingham. Terminated at 1 site in United States. Open to participants aged 18 Years to 54 Years. Per ClinicalTrials.gov, last updated 2021-10-11.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

Why this study was terminated
Termination of study funding due to COVID-19
Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 54 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 21 studies in Multiple Sclerosis by University of Alabama at Birmingham — 2 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · University of Alabama at Birmingham.

Enrollment
17th of 20
14 · median 27
Started
2018
with 4 others
No phase
18 of 21
1 open now
Registered
4th of 21
by date

Among the 21 studies in Multiple Sclerosis by University of Alabama at Birmingham, this one is the 17th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2018, is one of 18 with no phase, and was the 4th registered.

Multiple Sclerosis

3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 21 studies in Multiple Sclerosis by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 430 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 211 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 54 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Multiple Sclerosis by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

The two primary study objectives involve examining the effects of treadmill walking exercise training versus stretching-and-toning activities on the primary and secondary outcomes.

Specific Aim 1: The first specific aim is to examine the effects of 3-months of treadmill walking exercise training compared with an active control condition on learning and memory outcomes in fully-ambulatory persons with MS who have impairment in learning new information. We hypothesize that those who undergo treadmill walking exercise training will demonstrate improvements in learning and memory relative to those who undergo stretching-and-toning activities.

Specific Aim 2: The second specific aim is to examine the effects of 3-months of treadmill walking exercise training compared with an active control condition on hippocampal volume, hippocampal resting-state functional connectivity, and cardiorespiratory fitness in those persons with MS. We hypothesize that those who are randomly assigned to the treadmill walking exercise condition will demonstrate increases in hippocampal volume and resting-state functional connectivity (i.e., adaptive increases) and improved cardiorespiratory fitness relative to those in the stretching-and-toning condition.

Read the detailed description

The proposed study involves a single-blind, Phase I randomized controlled trial (RCT) on the effects of supervised treadmill walking exercise training on learning and memory, hippocampal structure/function, and cardiorespiratory fitness outcomes in fully-ambulatory (i.e., EDSS ≤ 4.0) persons with multiple sclerosis (MS) who have impairment in learning new information. This study will compare the effects of 3 months of supervised, progressive (both intensity and duration) chronic treadmill walking exercise (designed based on pilot work [Sandroff et al., 2015; 2016a; 2016b] and American College of Sports Medicine (ACSM) guidelines) with those of an active control condition (i.e., stretching-and-toning activities) on learning and memory, hippocampal volume and resting-state functional connectivity, and cardiorespiratory fitness. Learning and memory represents the primary outcome, whereas hippocampal volume and resting-state functional connectivity and cardiorespiratory fitness represent the secondary outcomes. Such an investigation will provide the first Class I evidence for the effects of treadmill walking exercise training on those outcomes in MS.

During baseline, participants will first complete a battery of neuropsychological tests, followed by an incremental exercise test to exhaustion on a motor-driven treadmill to measure cardiorespiratory fitness, and will undergo a MRI scan. Those outcomes will be measured by assessors who are blinded to condition. Participants will undertake several neuropsychological tests addressing various aspects of learning and memory. These tests include the California Verbal Learning Test-2 [Delis et al., 2000] and Selective Reminding Task [Buschke \& Fuld, 1974] as measures of verbal learning and memory, and the Brief Visuospatial Memory Test-Revised [Benedict, 1997] and 10/36 Spatial Recall Test [Rao et al., 1984] as measures of visuospatial learning and memory. Cognitive processing speed will be measured using the Symbol Digit Modalities Test [Smith, 1982], verbal fluency will be measured using the Controlled Oral Word Association Test [Benton, 1994], and executive control (i.e., inhibitory control) will be measured using a modified flanker task [Eriksen \& Eriksen, 1974]. Cardiorespiratory fitness will be measured as peak oxygen consumption (VO2peak), using an incremental exercise test to exhaustion on a motor-driven treadmill and an open-circuit spirometry system (ParvoMedics True One 2400, Sandy, UT) for analyzing expired gases using a modified Balke protocol. This protocol is commonly used for measuring cardiorespiratory fitness in older adults [e.g. Colcombe et al., 2004] and persons with chronic stroke [e.g., Macko et al., 1997] and further is consistent with the ACSM guidelines for exercise testing of MS patients [ACSM, 2013]. Lastly, participants will undergo structural and resting-state functional connectivity magnetic resonance images of the hippocampus. The MR instrument that will be used is an FDA-approved Siemens 3 T clinical imager. Following baseline testing, participants will be randomly assigned to either the exercise training or active control condition using concealment. Participants further will blinded to condition (i.e., unaware that the treadmill walking exercise training condition represents the experimental condition and the stretching-and-toning condition represents the active control condition).

The exercise training will include 3-months of supervised, progressive light, moderate, and vigorous intensity treadmill walking exercise, and will be based on ACSM guidelines for exercise prescription [ACSM, 2013]. We selected treadmill walking exercise as the aerobic exercise modality based on pilot work that suggests that treadmill walking might exert larger beneficial effects on cognition compared with stationary cycling [Sandroff et al., 2015], and that such benefits occur for light, moderate, and vigorous intensity treadmill walking exercise [Sandroff et al., 2016]. The exercise training itself will take place 3 times per week over 3 months, led by trained exercise leaders, and will initially consist of 15 minutes of light-to-moderate intensity treadmill walking exercise and eventually progress to 40 minutes of vigorous intensity exercise by month 3. The stretching-and-toning activities will be included as a minimal exercise, active control condition. The control condition will be delivered using the same frequency and duration of the treadmill walking exercise condition. The stretching-and-toning activities will be based on a manual provided by the National Multiple Sclerosis Society, and stretching-and-toning activities will be progressively included over the course of the 3-month study period. Participants will further be asked to not undertake additional exercise (i.e., not join a gym and begin exercising) over the duration of the study. The cognitive, cardiorespiratory fitness, and MRI outcomes will be assessed again following the 3-month study period by assessors who are blinded to condition.

The data will be analyzed using mixed-factor ANOVA with time (pre- and post-) as a within-subjects factor and condition (exercise or control) as a between-subjects factor on learning and memory, hippocampal, and cardiorespiratory fitness outcomes (see Specific Aims/Hypotheses 1 and 2 in the Primary Study Objectives and Study Hypothesis sections). Effect sizes will be expressed as partial eta-squared (ηp2) and Cohen's d [Cohen, 1988]. Spearman's rho rank-order correlations (ρ) will be performed for the associations among changes in cardiorespiratory fitness, hippocampal structure/function, and learning and memory for those who underwent the treadmill walking exercise training condition (See Specific Aims/Hypotheses 3 and 4 in the Secondary Study Objectives and Study Hypothesis sections). The effect sizes from the interaction terms from the ANOVAs and correlations will serve as effect sizes for the subsequent power analyses required for a subsequent Phase II RCT.

03

Conditions studied

  • Multiple Sclerosis
  • Physical Activity
  • Memory Impairment
  • Cognitive Change

Keywords

  • exercise
  • neuroimaging
  • walking
  • multiple sclerosis
04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion/Exclusion Criteria:

  • All participants will:
  • Be between the ages of 18-54 (Males 18-44; Females 18-54)
  • Have a clinically definite MS diagnosis based on established criteria
  • Be fully-ambulatory based on Expanded Disability Status Scale (EDSS) scores between 0-4.0
  • Demonstrate impairment in learning new information based on open-trial Selective Reminding Task scores at least 1.5 SD's below the normative score for healthy controls (i.e., 5th percentile)
  • Be relapse-free and will not have acutely taken for at least 30 days (i.e., relative neurologic stability)
  • Not have a history of major depressive disorder, schizophrenia, bipolar disorder I or II, or substance-abuse disorders.
  • Not be taking medications that can affect cognition (e.g., antipsychotics, benzodiazepines).
  • Be right-handed
  • Have corrected vision better than 20/80
  • Not have known/diagnosed cardiovascular, metabolic, or renal disease. Individuals with known/diagnosed cardiovascular, metabolic, or renal disease who are asymptomatic will be included only with a physician's approval.
  • Demonstrate scores on the (MMSE) of 21 or higher (no decisional impairment)
  • Be on a stable disease-modifying therapy regimen (i.e., at least 6 months prior to study enrollment).
  • Have a low risk for for MRI based on not having metal (e.g., non-MRI compatible aneurysm clips, metal shards in the body or eyes, or recently placed surgical hardware) or electronic devices (e.g., pacemaker, cochlear implant) within the body.
  • Not be pregnant
  • Not be engaging in ≥ 150 min of moderate-to-vigorous physical activity (i.e., not meeting public health guidelines for physical activity) per week
  • Not be actively engaging in cognitive rehabilitation, or participating in regular brain fitness activities
  • Demonstrate systolic blood pressure values of \< 200 mmHg or diastolic blood pressure values \< 110 mmHg at rest
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Treadmill Walking Exercise Training

    12 weeks of supervised, progressive treadmill walking exercise training

    Behavioral: Treadmill Walking Exercise Training

  • Active comparator
    Stretching-and-toning Exercise Training

    12 weeks of supervised, stretching-and-toning exercise training

    Behavioral: Stretching-and-toning Exercise Training

Interventions

  • BehavioralTreadmill Walking Exercise Training

    12-weeks of supervised, progressive treadmill walking exercise training

  • BehavioralStretching-and-toning Exercise Training

    12-weeks of supervised, stretching-and-toning exercise training

06

What researchers measure

Primary outcomes

  1. Composite Learning and Memory Performance

    Composite z-score of performance on California Verbal Learning Test-II, Selective Reminding Task, Brief Visuospatial Memory Test-Revised, and 10/36 Spatial Recall Test

    Time frame: Baseline to 12-week follow-up

Secondary outcomes

  1. Hippocampal Volume

    Volume of bilateral hippocampi measured using structural MRI

    Time frame: Baseline to 12-week follow-up

07

Study locations

1 site
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-0104, United States
08

References and documents

Publications

  • Sandroff BM, Wylie GR, Baird JF, Jones CD, Diggs MD, Genova H, Bamman MM, Cutter GR, DeLuca J, Motl RW. Effects of walking exercise training on learning and memory and hippocampal neuroimaging outcomes in MS: A targeted, pilot randomized controlled trial. Contemp Clin Trials. 2021 Nov;110:106563. doi: 10.1016/j.cct.2021.106563. Epub 2021 Sep 5. PubMed 34496278 ↗
  • Sandroff BM, Motl RW, Bamman M, Cutter GR, Bolding M, Rinker JR, Wylie GR, Genova H, DeLuca J. Rationale and design of a single-blind, randomised controlled trial of exercise training for managing learning and memory impairment in persons with multiple sclerosis. BMJ Open. 2018 Dec 14;8(12):e023231. doi: 10.1136/bmjopen-2018-023231. PubMed 30552263 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Mar 2020, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2017
First posted
Oct 24, 2017
StartActual
Dec 1, 2018
Primary completionActual
Mar 16, 2020
CompletionActual
Jan 3, 2021
Last update
Oct 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03319771
Collaborators
EMD Serono
Responsible party
Brian Sandroff (Principal Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Oct 24, 2017
Start date
Dec 1, 2018
Primary completion
Mar 16, 2020
Completion
Jan 3, 2021
Last update
Oct 11, 2021

Study contacts

Brian M Sandroff, PhD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion